Predicting Progression of Developing Myeloma in a High-Risk Screened Population
- Conditions
- Healthy
- Registration Number
- NCT05837884
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria:<br><br> - Must meet criteria of the high-risk population as described with one of the below<br> criteria<br><br> - = 30 years AND<br><br> - first-degree relative of a patient with a plasma cell dyscrasia such as MGUS,<br> SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.<br><br>OR<br><br> - Age = 18 years with 2 or more first- or second-degree relatives with a plasma cell<br> dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another<br> blood cancer '<br><br> - Voluntary written informed consent must be given with the understanding that consent<br> may be withdrawn by the patient at any time without prejudice to future medical care<br><br>Exclusion Criteria:<br><br> - • Persons diagnosed with cancer at any site (including hematologic cancers) with<br> symptomatic disease requiring active therapy.<br><br> - Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM,<br> and Waldenström's Macroglobulinemia<br><br> - Female patient who have a positive serum pregnancy test during the screening<br> period or a positive pregnancy test.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence and Incidence
- Secondary Outcome Measures
Name Time Method Presence of clinical alterations;Determination of natural history of screen-detected vs. incidentally detected MGUS/SMM;Determination clinical and epidemiological risk factors